Aug 30, 2025 ketamine

Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)

Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.

by Michael DeMarco, PhD

(2025) Ketamine is a prototypical rapid-acting antidepressant for treatment-resistant bipolar depression (TRBD), yet many patients do not achieve a meaningful response.

Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression

"Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis."

30 Aug

Is ketamine a "psychedelic"?

Yes.

29 Aug

Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)

"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."

29 Aug

Spotlight: A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Mus musculus) (Rocha, et al, 2025)

"No significant alterations were observed in liver and kidney function in either sex, nor in inflammation, apoptosis, or DNA damage in kidney tissues. Overall, these findings support the viability of voluntary oral ketamine administration and accentuate the need to refine the proposed model"

28 Aug

Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)

"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."

27 Aug

Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative

"The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling adoption in hospital, outpatient, and home-care settings."